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Abstract
Using the New England BioLabs (NEBL) SNAP-based Genes Expression 
in conjunction with our “sub-micron arrays” (Anodic Porous Allumina and/
or Kapton based Nanopores), we exploit our proprietary microarrays scanner 
(DNASER, DNA analyzer) and Label Free Nanotechnologies to carry out the 
following tasks: 
1) Construction of SNAP-based Genes Nanoarrays, using gold surface 
coated for 10 minutes with 2% solution of 3-Aminopropyltriethoxysilane 
(APTES) in acetone, rinsed in acetone and dried with filtered air. Full length 
complementary DNAs (cDNAs) for onco-suppressor 53 (p53), Cyclin-dependent 
kinase 2 (CDK2), SH2 (Src Homology 2) domain of the proto-oncogene 
tyrosine-protein kinase (Src) and tyrosine-protein phosphatase non-receptor 
type 11 (PTPN11) were amplified and cloned. Printing mix was prepared with 
0.66 μg/μl DNA capture reagent BG-PEG-NH2 for the one-step synthesis of 
SNAP-tag substrates from esters on labels or surfaces;
2) Determination of Protein-Protein Interaction for the chosen cancer 
following the identification of leader genes (or hub genes, investigated with 
theoretical ab initio bioinformatics analysis using in-house software and 
algorithms, and then experimentally confirmed via DNASER). These genes are 
expressed by Pure (Protein synthesis Using Recombinant Elements) Express in 
spots less than 1 micron size piezo-microdispensed and then characterized via 
Label Free proprietary Autoflex Mass Spectrometry (MS) integrated with ad hoc 
software, namely the Spectrum Analyzer and Data Set manager (SpADS) and 
a proprietary Quartz Crystal Micro-balance with Dissipation factor monitoring 
(QCM_D) Nanoconductimetry, enabling to describe properties such as changes 
in frequency and conductance, viscoelasticity and dissipation factor. Solutions 
without DNA were prepared (called Master Mix, MM), as negative controls, 
in printing mix. Negative controls were prepared with a varying concentration 
range of SNAP capture reagent. As a positive control (for fluorescence analysis) 
mouse IgG or rabbit IgG (Pierce, IL, USA) were added in a printing mix instead 
of DNA. 
Keywords 
Quartz Crystal Microbalance with Dissipation Factor monitoring (QCM_D) 
and Nanoconductimetry, SNAP microarrays, Mass Spectrometry (MS)
Introduction
On the light of the sixteen recently published experimental papers, referenced 
in the last section [1-16], we have successfully completed the feasibility study on 
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negative controls, in printing mix. Negative controls were 
prepared with a concentration range from 80 to 800 ng/µl of 
SNAP capture reagent. As a positive control (for fluorescence 
analysis) mouse IgG or rabbit IgG (Pierce, IL, USA) were 
added in a printing mix instead of DNA.
Results
In Figures 1-6 we show what we experimentally 
obtained. The results are obtained applying our innovative 
conductometer, realized by combining Nucleic Acid 
Programmable Protein Arrays (NAPPA) technology with 
QCM_D, to the characterization of protein-protein and 
protein-sterol interactions in a multiparametric way, taking 
advantage of the multiple information provided by the analysis 
of the conductance curves (i.e. conductance, viscoelasticity and 
adsorbed mass, which can be estimated using the Sauerbrey 
equation). 
Moreover, through our Nanoconductometer we acquired 
information on the kinetic constant of enzymatic interaction. 
The protocol for properly performing Nanoconductimetric 
assay is shown in Figure 1. Piezoelectric inkjet printing offers 
the possibility of spotting on complex surfaces and using 
clinical samples of limited volume and amount, while QCM_D 
discriminates several genes per spot contrary to the single one 
with fluorescence [Figure 2]. We investigated well known 
pairs of interacting molecules like Cholesterol side-chain 
cleavage enzyme 11A1 (CYP11A1) and Cholesterol, Jun and 
Activating Transcription Factor 2 (ATF2), p53 and MDM2. 
two distinct but highly correlated lines of research in progress 
since 2012. On the basis of these obtained findings, we have 
subsequently prepared several proposals to be submitted as 
grant applications to the Small Business Innovation Research 
(SBIR) program, along with a small company based in the 
United States of America (USA), being presently identified. 
We have identified the technologies we intend to use: 
namely, the New England BioLab (NEBL) proprietary 
“SNAP (Single Nucleotide Amplified Polymorphism) based 
Genes Expression” in conjunction with our proprietary “Sub-
micron Arrays” (either our Anodic Porous Allumina – APA 
– Nanopores and/or Kapton based Nanopores, in cooperation 
with Arts Engineering), our proprietary microarrays scanner 
DNASER (DNA Analyzer) and Label Free Nanotechnologies 
resulting from a collaboration between the Laboratories 
of Biophysics and Nanobiotechnology (LBN) at Genoa 
University, Department of Experimental Medicine (DIMES), 
Genoa, Italy and Fondazione EL.B.A. Nicolini (FEN), 
Pradalunga (Bergamo), Italy. 
Namely, we intend to carry out: 
1) Construction of SNAP Genes Nanoarrays, using 
gold surface coated for 10 minutes with 2% solution of 3- 
Aminopropyltriethoxysilane – APTES – (Pierce, Rockford, 
IL, USA) in acetone, rinsed in acetone and dried with filtered 
air. Full length complementary DNAs (cDNAs) for onco-
suppressor protein 53 (p53) and Cyclin-dependent kinase 2 
(CDK2) were both purchased form DNASU Central Plasmid 
Repository located in the Biodesign Institute, Arizona 
State University (ASU), USA (https://dnasu.org/DNASU/
Home.do). Full length cDNAs for the SH2 domain of the 
proto-oncogene tyrosine-protein kinase (Src) and tyrosine-
protein phosphatase non-receptor type 11 (PTPN11) were 
purchased from Open Biosystem, Thermo Scientific. cDNAs 
were amplified and cloned into NdeI and XhoI sites in 
pCOATexp SNAPf vector, a derivative of pCOATexp and 
pSNAPf (further details can be found at (https://www.neb.
com/products/n9183-psnapf-vector#tabselect0). Printing 
mix was prepared with 0.66 µg/µl DNA [bovine serum 
albumin, BSA, bound], capture reagent: BG-PEG-NH2 (an 
amine-terminated building block for the one-step synthesis 
of SNAP-tag substrates from NHS esters or other activated 
carboxyl esters on labels or surfaces, https://www.neb.com/
products/s9150-bg-peg-nh2), ranging from 80 to 800 ng/µl 
[sBS3 bound]. 
2) Determination of Protein-Protein Interaction for the 
chosen cancer following the identification of genes leaders 
(hub genes, being highly interconnected and investigated via 
bioinformatics analysis and then experimentally confirmed via 
DNASER) expression by PureExpress in spots sized less than 
1 micron size piezo-microdispensed (as well proprietary) and 
characterized via Label Free proprietary dedicated Autoflex 
Mass Spectrometry (MS) integrated with ad hoc software 
such as the proprietary Spectrum Analyzer and Data Set 
manager (SpADS)  and a proprietary Quartz Crystal Micro-
balance with Dissipation factor monitoring (QCM_D) 
Nanoconductimeter for performing nanoconductimetry. 
Solutions without DNA (master mix, or MM) were prepared, 
Figure 1: Our proprietary nanoconductomer for performing 
nanoconductimetry, developed by successfully coupling Quartz Crystal Micro-
balance with Dissipation factor monitoring (QCM_D) with Nucleic Acid 
Programmable Protein Arrays (NAPPA) technology.
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An interesting implication for potential clinical applications 
concerned furthermore the possibility to drastically reduce the 
time of protein expression and capture under our experimental 
conditions. 
The QCM_D instrument we used allowed us to monitor 
in real time the trend of Dissipation factor (D factor) and 
frequency (f ) during the interaction between CYP11A1 
and Cholesterol, both in solution and in blood. Assuming a 
Michaelis-Menten like behavior and fitting these experimental 
data, we were able to compute a constant (K) of about 100 
µM, a value which is in good agreement with the values 
found in the extant literature. Finally, in order to verify the 
possibility to analyze simultaneously more interactions in a 
single NAPPA-Quartz Crystal (QC), we immobilized on the 
same QC up to three cDNAs. In our hands, we were able to 
successfully identify all of them and, subsequently, we analyzed 
the response to multi-protein interactions. Jun & CDK2 and 
Jun & CDK2 & p53 co-expressed in the same QCs were 
indeed tested for ATF2 interaction, both in flow and statically. 
Taken all together, we demonstrated the versatility of the 
NAPPA-QC biosensors for the detection of protein-protein 
interactions and protein-sterol interaction in cancer control as 
well as for controlling other diseases. Moreover, we measured 
also interaction between genes and their products and drugs 
(such as Temozolomide, commercially known as Temodar, an 
antiblastic used for brain cancer), showing that our proprietary 
instrument is able to perform both genomics and proteomics/
pharmacogenomics and pharmacoproteomics (shown in 
Figure 3). QCM_D is multi-purpose and, furthermore, is a 
very quick and effective tool for characterizing a biochemical 
system.
The analysis of self-assembling protein microarray 
NAPPA expressed with the SNAP tag in Escherichia coli 
coupled self free expression system prove capable to develop a 
highly standardized procedure in order to analyze the protein-
protein interaction occurred on the array combining label 
free MS. We employ in the process PURE (Protein synthesis 
Using Recombinant Elements) system. 
For the first time an improved version of NAPPA, that 
allows for functional proteins to be synthesized in situ – with 
a SNAP tag – directly from printed cDNAs prepared just 
in time for the assay, has been expressed with a novel cell-
free transcription/translation system reconstituted from the 
purified components necessary for Escherichia coli translation 
– the PURE system – and analyzed in a label free manner 
by three different mass spectrometry techniques, namely 
Figure 2: Piezoelectric liquid dispensing (left) for printing and probing of 
NanoProbeArrays of June, CDK2 and p53.
Figure 3: QCM_D conductance curves for MM_MLH1 and POLB 
interacting with Temozolomide at increasing concentrations. Figure 4: Mass Spectrometry   NAPPA versus SNAP arrays.
Figure 5: Mass Spectrometry of Snap-Nappa Arrays of p53 versus CdK2 genes 
expressed using PURE E. Coli system.
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two Matrix Assisted Laser Desorption Ionization Time-of-
Flight (MALDI-TOF), a Voyager and a Bruker Ultraflex, 
and a Liquid Chromatography-Electrospray Ionization 
Mass Spectrometry (LC-ESIMS/ MS). Autoflex Mass 
Spectrometry shows discrimination of NAPPA versus SNAP 
arrays [Figure 4] and of different genes as p53 versus CdK2 
genes expressed using PURE E. Coli system [Figure 5]. Due to 
the high complexity of the system, very difficult results were 
obtained and, therefore, in order to reduce this complexity and 
make sense of the findings, there was the need to develop and 
design an ad hoc bioinformatics tool for the analysis [Figure 
6]. Furthermore, a contemporary fluorescence analysis of 
NAPPA, expressed by means of PURE system, has been 
performed to fully characterize this new NAPPA SNAP 
system and correlated to pure MS results.
We have recently developed a new MS bioinformatics 
procedure here reported for the first time. Instead of using 
a statistical approach, we started from all the components of 
the PURE mixture. All the hundred proteins of PureExpress 
mixture (15) have been indeed plotted against the peaks 
experimentally obtained of background acquired with our 
Mass Spectrometer [Figure 7]. 
The biophysical unit is m/z ratio (of PureExpress along x 
axis and of background experimentally acquired along y axis). 
All the peaks have been accordingly normalized, assuming 
constant equimolar ratios (1:1:1:.. for all the components), or, 
in other words, assuming that intensity of the peaks (relative 
abundance) is equal for all the components. Observing this 
scatterplot, an exceptional alignment of both components 
(peaks of PureExpress and those experimentally acquired) 
emerges. It can be anticipated from this scatterplot that, 
knowing the real, exact molar ratios, the signal would be more 
or less perfectly subtracted.
Conclusion
The two combined Label Free technologies, MS integrated 
by proprietary software and technology, new ad hoc proprietary 
bioinformatics tools, and QCM_D Nanoconductometry 
integrated by proprietary hardware and software, as applied 
to optimized microarray with micron sized genes spots using 
SNAP and bacterial lysate technologies further optimized in 
a future application for SBIR program, may be constructed 
in such further optimized way to overcome multiple gene 
expression and interaction in a fashion unmatchable by current 
fluorescence technology using single gene, oversized spots. The 
approach described in Figure 7 is different from the clustering 
approach (shown in Figure 6) in that is more effective, less 
complex and can be routinely used also in clinical contexts.
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